According to results of a recent study, maternal exposure to cetirizine (CTZ) during pregnancy is not associated with an increased risk of adverse outcomes.
To assess pregnancy outcomes associated with CTZ use, a retrospective analysis was conducted using the UCB Pharma Patient Safety Database to search for pregnancies up to February 28th, 2015. Data reporting maternal CTZ exposure was obtained and outcomes such as comorbidities and infant events were assessed.
The authors reported that of the total 522 CTZ-exposed pregnancies extracted, 228 had available outcomes and 49 were prospective. “The majority (83.7%) resulted in live births; 4 spontaneous miscarriages, 3 induced abortions and 1 stillbirth were reported,” the authors stated. They added, “Most pregnancies were exposed during the first trimester.” Additionally, congenital malformations were reported in 2 of the 41 live births from CTZ-exposed pregnancies.
Maternal exposure of CTZ during pregnancy was not found to be associated with adverse pregnancy outcomes. The study authors concluded, “While the limitations of a safety database study need to be considered, the results shown here are reassuring.”
Schlit AF et al. Safety of cetirizine in pregnancy. Journal of Obstetrics and Gynaecology. DOI: 10.1080/01443615.2018.1441271.